The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
 
Rashmi Bhakuni
Patents, Royalties, Other Intellectual Property - Co-author; "SUBSTITUTED 1,2- DIHYDRO-3H-PYRAZOLO[4,3-C]QUINOLIN-3-ONE AS ATR KINASE INHIBITORS", granted by the Government of India on June 19th, 2023. (Inst)
 
Evan Hall
Research Funding - Cullinan Oncology (Inst); Gilead Sciences (Inst); ImCheck therapeutics (Inst); Immunocore (Inst); Kezar Life Sciences (Inst); NiKang Therapeutics (Inst); Pfizer (Inst); Replimune (Inst)
 
Ted Gooley
Consulting or Advisory Role - Regimmune
 
Yvonne Mowery
Employment - Duke Health Private Diagnostic Clinic; UPMC Hillman Cancer Center/University of Pittsburgh
Honoraria - Oakstone; UpToDate
Consulting or Advisory Role - Catalys Pacific
Research Funding - Merck (Inst)
 
George Ansstas
Consulting or Advisory Role - Immunocore; Regeneron
 
Andrew Brohl
Consulting or Advisory Role - Deciphera
Research Funding - Merck (Inst)
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Maya Dimitrova
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer
 
Ling Gao
No Relationships to Disclose
 
Gino In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Georgiamune (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); TuHura (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Jeffrey Ishizuka
Stock and Other Ownership Interests - Curios Therapeutics
Consulting or Advisory Role - Danger Bio; Fortress Biotech; Ono Pharmaceutical; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".
 
Jose Lutzky
Consulting or Advisory Role - Aulos Bioscience; Castle Biosciences; Delcath Systems; Iovance Biotherapeutics
Research Funding - AsherBio (Inst); Aulos Bioscience (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); Immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Perspective Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); Syntrix Biosystems (Inst); Tango Therapeutics (Inst); TScan Therapeutics (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Erasca, Inc
 
Theresa Medina
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst)
 
Soo Park
Consulting or Advisory Role - Regeneron; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Regeneron (Inst); Replimune (Inst)
 
Samuel Saibil
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Medison; Novartis; Pfizer
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Ann Silk
Stock and Other Ownership Interests - gral; Illumina
Consulting or Advisory Role - Immunocore; Merck; Regeneron; Sun Pharma; Teva
Research Funding - Checkmate Pharmaceuticals (Inst); Marengo Therapeutics (Inst); Merck (Inst); Natera (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Judy Murray
No Relationships to Disclose
 
Steven Gore
No Relationships to Disclose
 
Suzanne Topalian
Stock and Other Ownership Interests - Arcturus Therapeutics; Atengen; Clasp Therapeutics (I); Dracen (I); Dragonfly Therapeutics; Enara Bio (I); RAPT Therapeutics (I); Tizona Therapeutics, Inc. (I); Winnow Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Arcturus Therapeutics; Bristol-Myers Squibb/Celgene; Compugen (I); Dracen (I); Dragonfly Therapeutics; GE Healthcare; Genmab; Immunomic Therapeutics (I); Normunity (I); PATHAI; RAPT Therapeutics (I); Regeneron; Regeneron (I); Takeda (I); Tizona Therapeutics, Inc. (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Immunomic Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb (I); Immunonomic Therapeutics (I); Intellectual property related to MSI as an immunotherapy biomarker.
Travel, Accommodations, Expenses - Dragonfly Therapeutics
 
Paul Nghiem
Leadership - Society for Investigative Dermatology (SID)
Honoraria - UpToDate
Consulting or Advisory Role - Almirall
Research Funding - Incyte (Inst)
Patents, Royalties, Other Intellectual Property - Patent filed: "Merkel cell polyomavirus T antigen-specific TCRs and uses thereof" (Inst); Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.